Consider a long position in Spruce Biosciences (SPRB), with a near-term price target of $200-$300 based on its promising rare disease drug and a proven business model. The entire Quantum Computing sector, including tickers like IonQ (IONQ) and BTQ Technologies (BTQ), is viewed as a strong avoid or short candidate due to a lack of viable technology. For an event-driven trade, consider shorting Capricor Therapeutics (CAPR) ahead of its upcoming HOPE-3 trial data, which is expected to fail. Sarepta Therapeutics (SRPT) presents another attractive long opportunity following recent positive three-year clinical data. Other biotech stocks mentioned favorably for long positions include Unicure (QURE) and Abivax (ABVX).

Spruce Biosciences (SPRB)

• The speaker is extremely bullish on SPRB, stating, "I'm buying it" and "I don't think it's too late."
• Price Targets: The speaker mentions several potential price targets, believing it could go to $200 or $300 pretty soon and potentially $500 or $600, maybe more in the long term. He notes he got in around $35.
• Investment Thesis:
  • Spruce acquired a promising drug for the rare disease Sanfilippo B from BioMarin (BMRN). BioMarin sold the asset for very little to focus on a different drug that ultimately failed, creating a significant opportunity for Spruce.
  • The drug is an Enzyme Replacement Therapy (ERT), a well-understood and historically successful business model pioneered by Genzyme. Wall Street is familiar with this model, making it an "easy to understand" story.
  • The speaker compares Spruce's potential to Catalyst Pharmaceuticals (CPRX), which also acquired a drug from BioMarin and saw its market cap grow to $2.5 billion.
  • He estimates the drug could generate $400 million in revenue. Applying a standard 5x sales multiple for biopharma suggests a potential $2 billion market cap, compared to its current valuation of around $250 million.
  • Recent clinical data is very strong, showing that the drug reduces the harmful substance that causes the disease "to normal" levels in patients.
  • The management team at Spruce includes former BioMarin employees who are experts in this specific area.
• Dilution Risk: The company recently raised money through a PIPE (private investment in public equity). While this diluted shareholders, the speaker is not concerned, as he had already factored in an even larger potential dilution in his own financial models.

Takeaways

• The speaker sees SPRB as a strong buy, even after its recent price increase.
• The investment is based on a clear, fundamental thesis: a proven drug class for a rare disease, a successful business model, and a strategic misstep by a larger company (BMRN) that created the opportunity.
• The potential upside is significant, with the speaker suggesting the stock could be worth many multiples of its current price. This is presented as a core long-term holding.

Quantum Computing Sector (General)

• The speaker holds an extremely bearish view on the entire quantum computing sector, calling it "all fraud" and comparing the hype to "fairy tales" and "meme coins."
• He believes the technology is nowhere near being commercially viable. He cites a Jefferies report stating that useful quantum computing is at least a decade away and would require technology (e.g., a million stable qubits) that is far beyond current capabilities.

Takeaways

• Investors should be extremely cautious and avoid investing in quantum computing stocks based on the current hype.
• The speaker believes the recent rallies in these stocks are driven by pure speculation ("dumbass market shenanigans") and are disconnected from any real business fundamentals.

IonQ (IONQ)

• Sentiment: Very Bearish.
• The speaker explicitly calls IONQ a "fairy tale" and mocks the idea that it could become a major tech company like Nvidia.
• He notes that a key insider, Peter Chapman, has reportedly sold his shares and exited the company completely.

Takeaways

• This is a strong signal to sell or avoid IONQ. The company is lumped in with the general quantum computing hype that the speaker believes is fraudulent.
• Insider selling is presented as a major red flag.

BTQ Technologies (BTQ)

• Sentiment: Very Bearish. The speaker states, "I want to short this BTQ" and "This thing's a fucking zero."
• After a quick review of the company's public filings, he notes several red flags:
  • It is a Canadian company, which he views skeptically (with the exception of Shopify).
  • It has negligible revenue (around $50 US dollars after conversion, he jokes).
  • He believes it is simply a shell company trying to capitalize on the quantum computing trend.

Takeaways

• The speaker identifies BTQ as a prime short-selling candidate.
• The company appears to have no real business or revenue, making its valuation highly questionable.

Sarepta Therapeutics (SRPT)

• Sentiment: Bullish. The speaker says, "I like Sarepta" and notes that recent data looks good.
• Context:
  • He mentions that Sarepta is presenting at the World Muscle Society and that the three-year data that was released "looks pretty good."
  • He includes SRPT in a short list of other biotech stocks he is positive on.

Takeaways

• SRPT is presented as a "long" idea.
• The positive clinical data is a key catalyst. Investors interested in the stock should research the latest data presented at the World Muscle Society.

Capricor Therapeutics (CAPR)

• Sentiment: Very Bearish. The speaker refers to the stock as "Kapper" and states it is "not a buy. Never has been a buy."
• He is actively looking for an opportunity to short the stock, calling a potential drop a "profit extravaganza."
• Context:
  • He is anticipating upcoming clinical trial data, stating, "Hope three is definitely gonna fail." This likely refers to the HOPE-3 trial for their Duchenne muscular dystrophy drug.
  • He calls the company a "one trick pony."

Takeaways

• CAPR is identified as a high-conviction short idea.
• The investment thesis is based on the prediction that the company's upcoming pivotal trial data will be negative, causing the stock to fall significantly. This is a high-risk, event-driven trade idea.

Other Investment Mentions

• Rigetti Computing (RGTI): Very Bearish. The speaker believes the company "doesn't actually have a business" and its massive trading volume is a sign of irrational market speculation, not fundamental value.
• D-Wave Quantum (QBTS): Very Bearish. He calls the company a "zero" and is shocked by its high valuation.
• BioMarin Pharmaceutical (BMRN): Bearish on Management. Used as a case study of poor corporate strategy. They sold off valuable assets (now owned by SPRB and CPRX) to chase a single blockbuster drug that failed. This serves as a cautionary tale for investors about scrutinizing management decisions.
• Nvidia (NVDA): Neutral/Observational. The speaker is watching the dynamic between increasing AI model efficiency (which could require fewer GPUs) and the simultaneously increasing overall demand for computing power. This push-and-pull is a key factor for anyone invested in NVDA.
• Confluent (CFLT): Mentioned a rumor that the company is a potential buyout target.
• Unicure (QURE) & Abivax (ABVX): Mentioned briefly as other biotech stocks the speaker likes and considers "longs."